Professor of Regenerative Medicine at Oxford, Paul Riley has established himself as an internationally renowned researcher in the field of cardiovascular developmental biology and regenerative medicine. His work established the basis of a DIY mechanism of vessel and muscle repair following myocardial infarction, and has facilitated phenotypic screening of human epicardium for drug discovery. Professor Riley has underpinned the work on regeneration with fundamental discoveries in cardiovascular development aligned to the hypothesis that adult repair is triggered by developmental re-programming. In recent years he has pioneered studies on epicardium derived-cells, establishing the paradigm of activating resident progenitor populations towards vascular and muscle-repair in the injured adult heart. Professor Riley is the Chair of Development and Cell Biology in the Department of Physiology, Anatomy and Genetics, having been awarded a British Heart Foundation Personal Chair of Regenerative Medicine to support this position. He is also director of a recently established BHF Oxbridge Centre for Regenerative Medicine.
Anthony Atala, MD, earned his medical degree from the University of Louisville School of Medicine. He completed his residency at the University of Louisville and a fellowship at Harvard Medical School/Boston’s Children’s Hospital. He joined Wake Forest Baptist in 2006 as the founding director of the Wake Forest Institute for Regenerative Medicine and chair of the Department of Urology. As director of this Institute, Atala oversees a team of more than 400 researchers who are dedicated to developing cell therapies and engineering replacement tissues and organs. Atala is a recipient of many awards, including the Christopher Columbus Foundation Award, which is bestowed on a living American who is currently working on a discovery that will significantly affect society, and the World Technology Award in Health and Medicine, presented to individuals achieving significant, lasting progress. In 2011, he was elected to the Institute of Medicine of the National Academy of Sciences and was inducted to the National Academy of Inventors as a Charter Fellow in 2014. More than 12 applications of technologies developed in Atala’s laboratory have been used clinically. He is the editor of 14 books, including Principles of Regenerative Medicine, Foundations of Regenerative Medicine, Methods of Tissue Engineering and Minimally Invasive Urology. He has published more than 500 journal articles and has applied for or received over 250 national and international patents.
Dr. Finkbeiner is currently the Associate Director and Senior Investigator at the Gladstone Institute of Neurological Disease, the Director of the Taube/Koret Center for Neurodegenerative Disease Research, and a Professor of Neurology and Physiology at the University of California, San Francisco. Dr. Finkbeiner studies the molecular mechanisms that are responsible for learning, memory and neurodegeneration. Dr. Finkbeiner earned a bachelor’s degree from Wheaton College in 1986 and earned both an MD and a PhD in neuroscience from Yale University in 1991. He completed an internship in internal medicine and chief residency in neurology at University of California, San Francisco, followed by a research fellowship at Harvard Medical School, and in 1999 he was one of the first investigators at the Gladstone Institute of Neurological Disease. Dr. Finkbeiner established the Taube-Koret Center in 2009 to accelerate the development of drug therapies for patients suffering from conditions such as Huntington’s disease. A study based on results from the microscope became the most-cited paper in the field of neuroscience in the last decade.